+

WO2006035622A1 - Procédé de fabrication de facteur de nutrition nerveuse in vivo utilisant un potentiel élevé alternatif et dispositif de fabrication de facteur de nutrition nerveuse in vivo - Google Patents

Procédé de fabrication de facteur de nutrition nerveuse in vivo utilisant un potentiel élevé alternatif et dispositif de fabrication de facteur de nutrition nerveuse in vivo Download PDF

Info

Publication number
WO2006035622A1
WO2006035622A1 PCT/JP2005/017177 JP2005017177W WO2006035622A1 WO 2006035622 A1 WO2006035622 A1 WO 2006035622A1 JP 2005017177 W JP2005017177 W JP 2005017177W WO 2006035622 A1 WO2006035622 A1 WO 2006035622A1
Authority
WO
WIPO (PCT)
Prior art keywords
high voltage
constant
living body
generating means
vivo
Prior art date
Application number
PCT/JP2005/017177
Other languages
English (en)
Japanese (ja)
Inventor
Hiroji Yanamoto
Original Assignee
Japan Health Sciences Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Health Sciences Foundation filed Critical Japan Health Sciences Foundation
Priority to JP2006537681A priority Critical patent/JPWO2006035622A1/ja
Publication of WO2006035622A1 publication Critical patent/WO2006035622A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/10—Applying static electricity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to an in vivo neurotrophic factor production method and in vivo neurotrophic factor production apparatus using an alternating high potential. More specifically, the present invention relates to a technique for increasing a neurotrophic factor in a living body by placing the living body in an alternating high electric field and applying a potential stimulus to the living body.
  • An object of the present invention is to increase neurotrophic factors in vivo.
  • the viability of central nerves and peripheral nerve cells is enhanced, so that they are protected from cerebral ischemic diseases such as cerebral infarction, neurodegenerative diseases and nerve injury caused by cerebrospinal injury.
  • the growth of neuronal neurites promotes nerve plasticity and improves cranial nerve functions such as memory.
  • cerebrospinal injury is a pathological condition that shows various neurological dysfunction symptoms due to direct damage to nerves caused by trauma, degenerative diseases, etc., or damage to the nerve transmission pathway. For these symptoms It may be effective to enhance neurotrophic factors that enhance the viability of the vesicles themselves and restore lost neural networks by promoting neurite growth.
  • Ischemia refers to a state in which the blood supply has been reduced for some reason or a state in which the blood supply has been interrupted, and the blood flow is interrupted, and various injuries appear depending on the time or range.
  • ischemic diseases include angina pectoris and myocardial infarction that develop when the blood supply to the myocardium decreases, and cerebral infarction that develops when the blood vessels of the brain become obstructed for some reason.
  • Effective means for protecting heart and brain organs from ischemic diseases such as myocardial infarction or cerebral infarction include the treatment of hypertension, diabetes, hyperlipidemia, fattening, heart disease, etc. that exist as risk factors, or Improvement is important.
  • ischemic diseases such as myocardial infarction or cerebral infarction
  • Improvement is important.
  • Many cases suffer from brain injury or heart injury due to ischemic disease, and many patients suffer from sequelae or die.
  • a neurotrophic factor is a type of growth 'trophic factor that promotes the maturation of neurons and the extension of neurites at the stage of individual growth and development, and synapses between the central nerves or between the central and peripheral nerves. It is an in vivo molecule that contributes to the formation or formation of the neural network between the cranial nerve 'peripheral nerve and various innervating organs. In the process of neuronal development and differentiation, if there is no neurotrophic factor, the neuron will undergo apoptosis and die, so the presence of the neurotrophic factor in the neurodevelopment stage will help maintain the survival of the neuron. It is important. It is also known that when this factor increases after the end of growth and development, the viability of neurons increases, and it has the effect of protecting neurons from various stresses and diseases.
  • Patent Document 5 describes a pharmaceutical composition containing 1,5-di (pyridine_4_yl) -penta-1,4-gen-1-one and a neurotrophic factor. It has been.
  • BDNF brain-derived neurotrophic factor
  • This factor is thought to contribute to synaptic plasticity by promoting the differentiation of endogenous neural stem cells into neurons and the growth of neurites of immature or mature neurons. It is also known that increasing this factor increases the viability of immature or mature neurons. When this factor is abnormally reduced in the brain, in young neurons, impaired differentiation into neurons, and in mature neurons, neuronal regression and decrease in neurites and synapses, and the resulting neuronal function This can cause a decline in memory and cause depression.
  • Patent Document 1 Japanese Patent Laid-Open No. 58-146361
  • Patent Document 2 JP-A-7-284535
  • Patent Document 3 Japanese Patent Laid-Open No. 2000-42123
  • Patent Document 4 Japanese Unexamined Patent Publication No. 2003-126270
  • Patent Document 5 Special Table 2001—504470
  • Non-patent document 1 Naoki Miura and 7 others, “Antihypertensive effect of hypertension model animals (Dahl _S rats) under alternating high voltage potential”, Journal of the Japan Veterinary Medical Association, 54, P 472-475, 2001
  • the present inventor has conducted intensive research on a method for increasing neurotrophic factors in vivo in a reliable and safe manner, and that an AC high potential load that causes a systemic potential change including the brain is in vivo neurotrophic. It has been found that it has a factor-increasing action, and the present invention has been completed.
  • the invention according to claim 1 is an in vivo neurotrophic factor production method characterized in that a constant or fluctuating high voltage of alternating current is applied to a living body to produce and increase production of a growth / nutrient factor in the living body. About.
  • the invention according to claim 2 is a high voltage generation means for generating a constant or variable high voltage of an alternating current with an extremely low current from an input power supply, and a high voltage generated by the high voltage generation means for applying to the organism. And an energizing means, wherein a constant or variable high voltage of alternating current generated by the high voltage generating means is applied to the living body by the energizing means to produce and increase production of growth / nutrient factors in the living body.
  • the present invention relates to an in vivo neurotrophic factor producing device.
  • the invention according to claim 3 relates to the in vivo neurotrophic factor production device according to claim 2, wherein the AC high voltage generated by the high voltage generation means is 1000 to 30000 V .
  • the invention according to claim 4 is characterized in that the AC high voltage generated by the high voltage generating means is constant or fluctuates within a range of 500 to 50000 V.
  • the in vivo nerve according to claim 2 It is related with a trophic factor production device.
  • the invention according to claim 5 relates to a method for improving cranial nerve function, wherein a constant or variable high voltage of alternating current is applied to a living body to improve cranial nerve functions such as memory ability.
  • the invention according to claim 6 is an AC constant or variable high voltage with an extremely low current from the input power supply.
  • a high voltage generation means for generating a high voltage generated by the high voltage generation means, and an energization means for applying the high voltage generated by the high voltage generation means to the living body.
  • the present invention relates to a cranial nerve function improving apparatus characterized in that a voltage is applied to a living body by the energizing means to improve cranial nerve functions such as memory ability.
  • the invention according to claim 7 relates to the device for improving cranial nerve function according to claim 6, wherein the AC high voltage generated by the high voltage generating means is 1000 to 30000V.
  • the invention according to claim 8 is the improvement of cranial nerve function according to claim 6, wherein the alternating high voltage generated by the high voltage generating means varies in a constant or within a range of 500 to 50000V. Relates to the device.
  • the invention according to claim 9 relates to a method for preventing ischemic injury, characterized in that a constant or variable high voltage of alternating current is applied to a living body to grow and produce 'nutrient factors' in the living body. .
  • the invention according to claim 10 is a high voltage generating means for generating an AC constant or variable high voltage with an extremely low current from an input power supply, and a high voltage generated by the high voltage generating means for applying to the organism.
  • the present invention relates to a device for preventing ischemic injury.
  • the invention according to claim 11 relates to the apparatus for preventing ischemic injury according to claim 10, wherein the AC high voltage generated by the high voltage generating means is from 1,000 to 30,000 V.
  • the invention according to claim 12 is the ischemic injury according to claim 10, characterized in that the alternating high voltage generated by the high voltage generating means is constant or fluctuates within a range of 500 to 50000V. It relates to a preventive device.
  • an AC constant high voltage potential AC constant high electric field
  • AC fluctuation high piezoelectricity By applying a position (AC fluctuation high electric field), it is possible to promote the production of neurotrophic factors in vivo. As a result, the resistance to various diseases and injuries of the nervous system that are healthy or have a reduced function can be enhanced or recovered. Furthermore, it is possible to improve brain function and nerve function such as memory ability that is normal or deteriorated.
  • the in vivo neurotrophic factor production method and in vivo neurotrophic factor production apparatus according to the present invention can be applied to young and old men and women, animals and plants.
  • the living body is charged with a constant AC high voltage potential (AC constant high electric field) or an AC variable high voltage potential (AC variable high electric field).
  • AC constant high electric field AC constant high electric field
  • AC variable high electric field AC variable high electric field
  • the method for improving cranial nerve function and the device for improving cranial nerve function according to the present invention can be applied to young and old men and women and animals and plants.
  • an AC constant high voltage potential AC constant high electric field
  • an AC variable high voltage potential AC variable high electric field
  • the apparatus for preventing ischemic injury according to the present invention can be applied to young men and women, animals and plants.
  • the method for producing in vivo neurotrophic factor according to the present invention is the production of in vivo neurotrophic factor by placing the living body in AC constant high voltage electric field (AC constant high potential) or AC variable high voltage electric field (AC variable high potential). It has the effect
  • spreading suppression which is a reversible transient cell depolarization phenomenon, increases brain-derived neurotrophic factor, which is a kind of neurotrophic factor, in the brain.
  • This increase in brain-derived neurotrophic factor induces resistance to ischemic stress (ischemic resistance, cerebral infarction resistance).
  • electrical potential stimulation by spreading suppression increases the neurotrophic factor in the brain, and has the effect of increasing the viability of the brain.
  • the present inventor has hitherto known known stimuli that have the effect of causing known spread suppression, i.e., epileptogenic stimulation, cerebral ischemic stimulation, or depolarization action.
  • known spread suppression i.e., epileptogenic stimulation, cerebral ischemic stimulation, or depolarization action.
  • constant or fluctuating alternating high-potential loading increases in vivo neurotrophic factors without using chemical stimuli such as bringing a chemical into contact with the brain.
  • the load potential (electric field) level and the fluctuation potential width (electric field fluctuation width) of the AC constant or variable high voltage potential load applied to the living body are not particularly limited. ', 1000 to 10000V, preferably 3000 to 20000V can be displayed.
  • the applied potential level may be constant during the period of loading on the living body, but may vary regularly or irregularly.
  • the potential level fluctuation cycle and the potential level fluctuation range are not particularly limited. For the fluctuation period, 1 to 20 times per minute, for example, 500 V to 50000 V for the fluctuation range. Can do.
  • the AC frequency used is not particularly limited, and 50-60 hertz can be exemplified.
  • a high potential load In order to increase the neurotrophic factor in the living body, it is desirable to continuously apply a constant AC voltage or a variable high potential (hereinafter simply referred to as a high potential) load for a certain period.
  • the period during which the high potential load is applied is not particularly limited, but one to several high potential loads per day is given for a total of 5 minutes to 8 hours per day, and this is continuously performed for at least one week to two months. High potential, preferably every day or every other day, for a certain period of time It is desirable to cover the load.
  • the body part to which the high potential load is applied is not particularly limited. Usually, when a part of the body is in contact with a high electric field, a systemic load is instantaneously applied.
  • FIG. 1 is a block diagram showing an outline of an in vivo neurotrophic factor production apparatus (hereinafter sometimes simply referred to as production apparatus) according to the present invention.
  • the production apparatus (1) uses the potential generation means (11) and the energization means (17).
  • the production device (1) is equipped with a high voltage generation circuit (14) that can generate an alternating current with a very low current or a variable high voltage by supplying power from the power supply unit (16).
  • the energizing means (17) is provided to apply an extremely low current AC constant or variable high voltage generated by the high voltage generating circuit (14) to the living body.
  • the power supply unit (16) is provided to supply necessary power to the production apparatus (1).
  • an alkaline ion battery, a lithium ion battery, a 100V AC power supply, a 200V AC power supply, a noku A battery is used.
  • the production device (1) is provided with a conversion unit (not shown) that converts the DC power source into an AC power source.
  • the production device (1) is provided with a high voltage generation circuit (14), which can generate a high AC voltage.
  • the high voltage generation circuit (14) is a constant AC high voltage generation circuit used in a conventional potential therapy device, or an AC fluctuation high voltage generation circuit, specifically, a constant AC voltage of about 1000 to 100000V. Any device that can generate a high voltage or that has a variable function that can change the high voltage regularly or irregularly in the range of 500 to 50,000 V can be used without particular limitation. be able to.
  • the potential generating means (11) includes a control unit (12) and an operation unit (15).
  • the control unit (12) is composed of a CPU and the like, and input information from the operation unit (15) is preliminarily determined.
  • the production means (1) is controlled correctly by controlling the ON / OFF switching unit (13), which controls the supply of power from the power supply unit (16), the high voltage generation circuit (14), etc. Control each part so that it always functions.
  • the operation unit (15) is provided with various switches and the like, and can perform various operations of the production apparatus (1).
  • the operation unit (15) is provided with a power switch, a treatment time selection switch for selecting a treatment time, a selection switch for selecting a potential and a fluctuation range, and the like.
  • the treatment time selection switch selects the treatment time. For example, when the set treatment time elapses, the control unit (12) controls the ON / OFF switching unit (13) to turn off the power. To do.
  • the selection switch can set the potential applied to the energizing means (17) to an arbitrary value, for example, a constant potential at 1000V, 3000V, 5000V, 10000V, or a regular or irregularly varying potential.
  • the energization means (17) is provided for applying a high voltage generated by the high voltage generation circuit (14) to the living body. When a high voltage is applied to the living body, the energizing means (17) is insulated from the ground.
  • an electrode capable of applying a high voltage generated by the high voltage generating circuit (14) to the living body can be exemplified.
  • the production device (1) according to the present invention can be applied not only to humans but also to any animals and plants, and particularly preferably to mammals such as sushi, pigs, hidges, horses, sheep and monkeys. be able to.
  • FIGS. 2 and 3 are diagrams showing the usage state of the in vivo neurotrophic factor production method according to the present invention.
  • a living body (animal or plant or user) is in contact with the current-carrying means (17) insulated from the ground and is located in a constant or variable high-voltage electric field.
  • the current-carrying means (17) insulated from the ground and is located in a constant or variable high-voltage electric field.
  • the 2 lies down, first lay an insulating mat (20) on the floor (Y) to insulate the energizing means (17) from the ground, and then energize it.
  • the user (M) lies down in contact with the energizing means (17).
  • the potential generating means (11) is connected to the energizing means (17), and the user (M) can be placed in a constant high-voltage or variable high-voltage electric field by operating the preventive device by the operation unit.
  • an insulating mat (20) for insulating the energizing means (17) from the ground is used.
  • the energization means (17) may be arranged at a position in contact with the user (M).
  • the energizing means (17) may be arranged on the seat surface of the chair as shown in FIG. In addition, it may be placed on the back of the chair.
  • the energizing means (17) is connected to the production device (1), and the user (M) can be placed in the high-voltage electric field by operating the potential generating means.
  • the production method according to the present invention can increase neurotrophic factors in vivo. Therefore, the production method according to the present invention increases the neurotrophic factor in the living body, and as a result, the viability of the central nerve 'peripheral nerve cells can be increased. Therefore, the cerebral ischemic disease such as cerebral infarction, It can be used as a preventive method against neurodegenerative diseases and nerve injury caused by cerebrospinal injury. That is, the method for preventing ischemic injury according to the present invention can be configured in the same manner as the in vivo neurotrophic factor production method described above.
  • the production increase method according to the present invention increases neurotrophic factors in the living body, and as a result, the growth of neuronal neurites is promoted, so that the nerve plasticity increases and the cranial nerve function improves the cranial nerve functions such as memory ability. It can be used as an improvement method. That is, the method for improving cranial nerve function according to the present invention can be configured in the same manner as the above-described in vivo neurotrophic factor production method.
  • the method for increasing production according to the present invention increases the neurotrophic factor in the living body and, as a result, can promote the growth of new nerves, and therefore can be used as a method for promoting new nerve growth. That is, the method for promoting the growth of new nerves is the above-mentioned in vivo neurotrophic factor production. It can be configured in the same way as the raw method.
  • the production device according to the present invention can increase neurotrophic factors in a living body. Therefore, the production apparatus according to the present invention increases the neurotrophic factor in the living body, and as a result, the viability of the central nerve 'peripheral nerve cell can be enhanced, so that the cerebral ischemic disease such as cerebral infarction
  • the ischemic injury preventing apparatus can be configured in the same manner as the in vivo neurotrophic factor producing apparatus described above.
  • the production apparatus increases neurotrophic factors in the living body, and as a result, the growth of neuronal neurites is promoted, so that the nerve plasticity is increased and the cranial nerve function is improved to improve the cranial nerve functions such as memory ability. It can be used as an improvement device. That is, the cranial nerve function improving apparatus according to the present invention can be configured in the same manner as the in vivo neurotrophic factor producing apparatus described above.
  • the production apparatus according to the present invention increases the neurotrophic factor in the living body and, as a result, can promote the growth of new nerves, it can be used as a new nerve growth promotion apparatus. That is, the new nerve growth promoting device can be configured in the same manner as the in vivo neurotrophic factor producing device described above.
  • C57BL / 6J male mice aged 8-9 weeks are subjected to various alternating constant or variable high potential loads once a day for 5 hours by the in vivo neurotrophic factor producing device according to the present invention: for 3 weeks I was loaded every day. The brain was removed under general anesthesia, and the brain content of brain-derived neurotrophic factor, a kind of neurotrophic factor, was measured. The results are shown in Fig. 4.
  • the brain-derived neurotrophic factor content in the group with constant AC or variable high-potential load increased significantly in the brain compared with the untreated group. It was.
  • Example 2 A local cerebral ischemic load was applied to a mouse loaded with a constant alternating or variable high potential load under the conditions shown in Example 1, and then the cerebral infarct volume produced was measured. The results are shown in FIG. 5. As shown in FIG. 5, cerebral infarction was significantly reduced in the group subjected to high potential load compared to the untreated group.
  • the in vivo neurotrophic factor production method and production apparatus can produce and increase neurotrophic factor in vivo, and can enhance or restore neural function by acting on neurites. .
  • ischemic injury such as cerebral infarction or other cerebral nerve 'peripheral nerve injury' damage. It can be repaired and brain functions such as memory can be improved. Therefore, the in vivo neurotrophic factor production method having these actions can be used for various animals including humans.
  • FIG. 1 is a block diagram showing an outline of an in vivo neurotrophic factor production apparatus according to the present invention.
  • FIG. 2 is a diagram showing a use state of the in vivo neurotrophic factor production device according to the present invention.
  • FIG. 3 is a diagram showing a use state of the in vivo neurotrophic factor production device according to the present invention.
  • FIG. 4 is a graph showing the results of Example 1.
  • FIG. 5 is a graph showing the results of Example 2.
  • FIG. 6 is a graph showing the results of Example 3. Explanation of symbols

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)

Abstract

L’invention porte sur un procédé de fabrication de facteur de nutrition nerveuse in vivo et sur un dispositif utilisant un potentiel élevé alternatif pour accélérer la croissance d’un individu immature, renforcer la viabilité d’organes, ou réparer/renforcer la fonction cérébrale en produisant/en augmentant les facteurs de croissance/de nutrition dans l’organisme. La production/l’augmentation des facteurs de croissance/de nutrition dans un organisme peuvent limiter les dégâts infligés aux organes à la suite d’une maladie ischémique comme une attaque cardiaque ou cérébrale et réparer/renforcer la fonction cérébrale qui est normale ou s’est dégradée à la suite d’une maladie ou une blessure. Un dispositif de fabrication de facteur de nutrition nerveuse in vivo comprenant un moyen de production de haute tension pour générer une haute tension constante ou variable alternative d’un courant extrêmement faible à partir d’une alimentation d’entrée et un moyen d’électrification pour appliquer la haute tension générée à un organisme, caractérisé en que l’application de la haute tension constante ou variable alternative générée à l’organisme par le moyen d’électrification permet de produire ou d’augmenter les facteurs de croissance/de nutrition dans l’organisme.
PCT/JP2005/017177 2004-09-28 2005-09-16 Procédé de fabrication de facteur de nutrition nerveuse in vivo utilisant un potentiel élevé alternatif et dispositif de fabrication de facteur de nutrition nerveuse in vivo WO2006035622A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006537681A JPWO2006035622A1 (ja) 2004-09-28 2005-09-16 交流高電位を用いた生体内神経栄養因子産生方法及び生体内神経栄養因子産生装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004282081 2004-09-28
JP2004-282081 2004-09-28

Publications (1)

Publication Number Publication Date
WO2006035622A1 true WO2006035622A1 (fr) 2006-04-06

Family

ID=36118774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/017177 WO2006035622A1 (fr) 2004-09-28 2005-09-16 Procédé de fabrication de facteur de nutrition nerveuse in vivo utilisant un potentiel élevé alternatif et dispositif de fabrication de facteur de nutrition nerveuse in vivo

Country Status (2)

Country Link
JP (1) JPWO2006035622A1 (fr)
WO (1) WO2006035622A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015793A1 (fr) * 2006-08-01 2008-02-07 Hiroji Yanamoto appareil augmentant le facteur neurotrophe lié au cerveau et procédé visant à augmenter le facteur neurotrophe lié au cerveau

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0451968A (ja) * 1990-06-18 1992-02-20 Masuo Yamamoto 静電気医療健康機
JP2003126270A (ja) * 2001-10-26 2003-05-07 Nippon Serufu Medical Kk 高圧電位治療器
WO2003066162A2 (fr) * 2002-02-07 2003-08-14 Northstar Neuroscience, Inc. Procede et appareil modifiant les fonctions neurales de patients
JP2004516274A (ja) * 2000-12-21 2004-06-03 メドトロニック・インコーポレーテッド 電気的反応性プロモーターシステム

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0451968A (ja) * 1990-06-18 1992-02-20 Masuo Yamamoto 静電気医療健康機
JP2004516274A (ja) * 2000-12-21 2004-06-03 メドトロニック・インコーポレーテッド 電気的反応性プロモーターシステム
JP2003126270A (ja) * 2001-10-26 2003-05-07 Nippon Serufu Medical Kk 高圧電位治療器
WO2003066162A2 (fr) * 2002-02-07 2003-08-14 Northstar Neuroscience, Inc. Procede et appareil modifiant les fonctions neurales de patients

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015793A1 (fr) * 2006-08-01 2008-02-07 Hiroji Yanamoto appareil augmentant le facteur neurotrophe lié au cerveau et procédé visant à augmenter le facteur neurotrophe lié au cerveau
JP5272164B2 (ja) * 2006-08-01 2013-08-28 広二 柳本 脳由来神経栄養因子増加装置および脳由来神経栄養因子増加方法

Also Published As

Publication number Publication date
JPWO2006035622A1 (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
US11872394B2 (en) Treatment of pain using electrical nerve conduction block
Linderoth et al. Conventional and novel spinal stimulation algorithms: hypothetical mechanisms of action and comments on outcomes
US20190201687A1 (en) Methods and systems for treatment of spinal disorders using trans-spinal direct current stimulation
Ay et al. Vagus nerve stimulation reduces infarct size in rat focal cerebral ischemia
Varga et al. Transcranial direct current stimulation in refractory continuous spikes and waves during slow sleep: a controlled study
US10864373B2 (en) Systems for treatment of a neurological disorder using electrical nerve conduction block
US9694181B2 (en) Methods of treatment of a neurological disorder using electrical nerve conduction block
US20240033514A1 (en) Systems for treatment of a neurological disorder using electrical nerve conduction block
Klein et al. Mapping brain regions in which deep brain stimulation affects schizophrenia-like behavior in two rat models of schizophrenia
Sokal et al. Deep anterior cerebellar stimulation reduces symptoms of secondary dystonia in patients with cerebral palsy treated due to spasticity
Hyvärinen et al. Cutaneous electrical stimulation treatment in unresolved facial nerve paralysis: an exploratory study
CN101674862A (zh) 支气管收缩的电刺激治疗
Fregni et al. Pain in chronic pancreatitis: a salutogenic mechanism or a maladaptive brain response?
Grecco et al. Transcutaneous spinal stimulation as a therapeutic strategy for spinal cord injury: state of the art
Maatoug et al. Non-invasive and invasive brain stimulation in alcohol use disorders: A critical review of selected human evidence and methodological considerations to guide future research
Li et al. Transcranial direct current stimulation for spinal cord injury-associated neuropathic pain
Wang et al. Neural mechanism underlying task-specific enhancement of motor learning by concurrent transcranial direct current stimulation
CN113784750A (zh) 使用复合电磁场对疼痛进行多模态或多路复用电调制的方法和设备
Choi et al. Modulation of natural killer cell activity affected by electroacupuncture through lateral hypothalamic area in rats
Usami et al. Modulation of cortical synchrony by vagus nerve stimulation in adult rats
García-Alías et al. Electroceutical therapies for injuries of the nervous system
WO2006035622A1 (fr) Procédé de fabrication de facteur de nutrition nerveuse in vivo utilisant un potentiel élevé alternatif et dispositif de fabrication de facteur de nutrition nerveuse in vivo
Harvey et al. Cortical stimulation as an adjuvant to upper limb rehabilitation after stroke
JP5272164B2 (ja) 脳由来神経栄養因子増加装置および脳由来神経栄養因子増加方法
Yanamoto et al. High voltage electric potentials to enhance brain-derived neurotrophic factor levels in the brain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006537681

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载